Sylics is comitted to support CNS disease research, also during these challenging times

The outbreak of COVID-19 affects all of us worldwide in an unprecedented manner. This requires us all to prioritize care and take disruptive measures to stop spread of the virus. While the worldwide focus will remain on COVID-19 for the next few months, at Sylics we continue to support our clients and partners in CNS research in the best way possible. For this reason, we have implemented procedures to mitigate risk of spread of COVID-19. These measures allow us to continue already initiated drug efficacy and behavioral screening studies and initiate new studies. If you are planning new studies, or if you have any questions about collaborations or our products feel free to reach out to us.